Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. Tsang ES, et al. Among authors: bergsland ek. JCO Precis Oncol. 2024 Nov;8:e2400328. doi: 10.1200/PO.24.00328. Epub 2024 Nov 7. JCO Precis Oncol. 2024. PMID: 39509670 Clinical Trial.
Metastatic insulinoma-outcomes in the current era.
Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E. Masharani U, et al. Among authors: bergsland e. Oncologist. 2024 Oct 30:oyae275. doi: 10.1093/oncolo/oyae275. Online ahead of print. Oncologist. 2024. PMID: 39475415 Free article.
Withdrawal pain following patients discontinuing Trk inhibitors.
Chin A, Lindsay S, Bergsland EK, Kang H. Chin A, et al. Among authors: bergsland ek. J Oncol Pharm Pract. 2024 Aug 27:10781552241279196. doi: 10.1177/10781552241279196. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 39191376 Free article.
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. Maldonado E, et al. Among authors: bergsland ek. Cancer Res Commun. 2024 Jul 1;4(7):1793-1801. doi: 10.1158/2767-9764.CRC-24-0213. Cancer Res Commun. 2024. PMID: 38920407 Free PMC article. Clinical Trial.
Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Tsang ES, et al. Among authors: bergsland ek. JCO Precis Oncol. 2024 Jun;8:e2300494. doi: 10.1200/PO.23.00494. JCO Precis Oncol. 2024. PMID: 38865673 Clinical Trial.
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Chauhan A, et al. Among authors: bergsland e. CA Cancer J Clin. 2024 Jul-Aug;74(4):359-367. doi: 10.3322/caac.21840. Epub 2024 Apr 29. CA Cancer J Clin. 2024. PMID: 38685134 Free article. Review.
157 results